Items where authors include "Turner, D.P.J."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 5.

Article

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Dave, N., Albiheyri, R.S., Wanford, J.J. et al. (5 more authors) (2023) Variable disruption of epithelial monolayers by Neisseria meningitidis carriage isolates of the hypervirulent MenW cc11 and MenY cc23 lineages. Microbiology, 169 (2). ISSN 1350-0872

Mentzer, A.J. orcid.org/0000-0002-4502-2209, O’Connor, D. orcid.org/0000-0002-6902-9886, Bibi, S. et al. (66 more authors) (2023) Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 29 (1). pp. 147-157. ISSN 1078-8956

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

This list was generated on Sun Apr 28 22:32:27 2024 BST.